SCHEMBL5537835

SCHEMBL5537835

Fc1ccccc1CCCOc1cc[c]cc1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAOB P27338 5/20 0.45
TAAR1 Q96RJ0 3/20 0.44
PARP15 Q460N3 1/20 0.41
PARP14 Q460N5 1/20 0.41
PARP10 Q53GL7 1/20 0.41
KCNA3 P22001 1/20 0.39
S1PR1 P21453 2/20 0.39
S1PR3 Q99500 2/20 0.39
MPO P05164 1/20 0.39
IDO1 P14902 2/20 0.38
AOC3 Q16853 1/20 0.38
NPC1 O15118 1/20 0.37
CASP3 P42574 1/20 0.37
RAB9A P51151 1/20 0.37
SENP8 Q96LD8 1/20 0.37
SENP7 Q9BQF6 1/20 0.37
SENP6 Q9GZR1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5542124 0.92 MAOB (0.46) MAOBTAAR1PARP15PARP14PARP10
SCHEMBL863430 0.81 MAOB (0.60) MAOBPARP15PARP14PARP10IDO1
SCHEMBL27629702 0.80 TAAR1 (0.43) MAOBTAAR1KCNA3IDO1AOC3
SCHEMBL5535257 0.80 MAOB (0.45) MAOBKCNA3IDO1
SCHEMBL8639387 0.78 ALDH1A1 (0.50) MAOBTAAR1PARP15PARP14PARP10
SCHEMBL15079868 0.77 CYP1A2 (0.53) MAOBTAAR1PARP15PARP14PARP10
SCHEMBL27300139 0.75 KCNA3 (0.42) MAOBTAAR1KCNA3NPC1RAB9A
SCHEMBL919854 0.75 DRD2 (0.56) MAOBKCNA3S1PR1S1PR3IDO1
SCHEMBL27629438 0.75 MAOB (0.44) MAOBKCNA3IDO1
SCHEMBL28756697 0.74 MAOB (0.43) MAOBKCNA3IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAOB 2140/4885TAAR1 364/4885PARP15 4183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.